http://www.anjarium.com/  

8952 Schlieren, Wagistrasse 23

 +41 44 552 38 88
 info@anjarium.com

Anjarium Biosciences AG is a genetic medicines company focused on creating and delivering a new generation of targeted gene therapies to patients. Anjarium’s versatile platform builds on novel therapeutic payloads and delivery technologies, with the aim to unlock the full potential of gene therapy.

https://www.arcorisbio.com/  

8952 Schlieren, Wagistrasse 18

 contact@arcorisbio.com

Kits and custom solutions for RNA FISH, Immunofluorescence, IHC, FACS and more.

https://www.athebio.com/  

8952 Schlieren, Grabenstrasse 11a

  +41 44 508 08 28
 hello@athebio.com

Athebio develops advanced binding molecules based on repeat proteins to help drug developers fill their pipelines with innovative drug candidates.

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.

http://www.biognosys.ch/  

8952 Schlieren, Wagistrasse 21

 +41 44 738 20 40
 info@biognosys.ch

BiognoSYS provides proteomics solutions to scientists and clinicians.

http://cdr-life.com/  

8810 Horgen, Tödistrasse 46

 info@cdr-life.com

CDR-Life is a Zurich-based biotech company that discovers and develops innovative medicines for the treatment of high need diseases. We invent and develop therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology.

http://www.cellerys.com/  

8952 Schlieren, Wagistrasse 21

Cellerys is a spin-off from University Hospital and University of Zurich. The company develops new therapies against Multiple Sclerosis (MS).

https://centenara.com/  

8952 Schlieren, Wagistrasse 18

 +41 44 730 12 90
 info@centenara.com

Centenara Labs develops and invests in therapies that target geriatric diseases. Our goal is to expand healthspan, promoting overall health, well-being and longevity as the population ages. Centenara Labs supports pioneers in the field of aging to transform their scientific discoveries into medicines. We are building a product pipeline comprised of potential breakthrough therapeutics that treat diseases of aging and help reduce the growing strain on global healthcare systems as the world’s population ages.

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor  

8952 Schlieren, Wagistrasse 25

 +41 58 851 80 00

Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.

http://cutiss.swiss  

8952 Schlieren, Grabenstrasse 11

 +41 44 244 36 60
 info@cutiss.swiss

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.